Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis-Reference-Cited by-同舟云学术

Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis

Published:2014-10 Issue:7 Volume:45 Page:570-579
ISSN:0188-4409
Container-title:Archives of Medical Research
language:en
Short-container-title:Archives of Medical Research

Author:

Su Guoqiang,Xiang Yi,He Guodong,Jiang Chenchun,Li Chuang,Yan Zhenyu,Zhong Yong

Publisher

Elsevier BV

Subject

General Medicine

Reference41 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer;Thurlimann;N Engl J Med,2005

3. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004

4. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial;Jakesz;Lancet,2005

5. Aromatase and its inhibitors: significance for breast cancer therapy;Simpson;Recent Prog Horm Res,2002

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials;Metabolism;2022-03

2. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis;Breast Cancer Research and Treatment;2020-04-21

3. The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2019-01

4. Safety of aromatase inhibitor therapy in breast cancer;Expert Opinion on Drug Safety;2015-06-09